NCT06173011View on ClinicalTrials.gov

A Study Comparing Pharmacokinetic and Safety of QL2107 and Keytruda® (Marketed in China and the United States) in Healthy Adults

PHASE1RecruitingINTERVENTIONAL
Enrollment

168

Participants

Timeline

Start Date

December 12, 2023

Primary Completion Date

July 31, 2024

Study Completion Date

July 31, 2024

Conditions
Tumor
Interventions
DRUG

QL2107

intravenous infusion 35 min (±5min, minimum infusion 30min), D1 (Day 1, single dose)

DRUG

Keytruda®(china)

intravenous infusion 35 min (±5min, minimum infusion 30min), D1 (Day 1, single dose)

DRUG

Keytruda®(US)

intravenous infusion 35 min (±5min, minimum infusion 30min), D1 (Day 1, single dose)

Trial Locations (1)

130000

RECRUITING

The First Affiliated Hospital of Jilin University, Changchun

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY